Date:3/6/2012

sses, including the acquisitions of i3 Global and PharmaNet Development Group, Inc., into our operations; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the potential liability associated with bringing new drugs to market, including potential liability from injury to clinical trial participants; and the actual impact of the adoption of certain accounting standards; our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Readers of this press release are referred to documents which may be filed from time to time by inVentiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.

PharmaNet/i3 Contact Information:
Name: Anne-Marie Hess
Phone: +1 609-951-6842
Email: ahess@pharmanet.com  

ASLAN Pharmaceuticals Contact Information:
Name: Sean Wong
Phone: +65 6222 4235
Email: media@aslanpharma.com

'/>"/>

SOURCE PharmaNet/i3; ASLAN Pharmaceuticals Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Access Pharmaceuticals Updates MuGard.com With New Product Testimonial
2. Aragon Pharmaceuticals Secures $42 Million in Series C Financing to Advance Pipeline of Therapies Targeting Hormone-Driven Cancers
3. Dr. Bogdan Dziurzynski Joins Anthera Pharmaceuticals Board of Directors
4. Jazz Pharmaceuticals Announces Public Offering of Ordinary Shares by Selling Shareholders
5. Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control
6. Idenix Pharmaceuticals Elects Thomas Hodgson as Chairman of the Board and Appoints Michael Wyzga to Its Board of Directors
7. Avanir Pharmaceuticals to Participate in Two Conferences in March
8. Endo Pharmaceuticals Announces Proposal to Change Name of Parent Company and Rebrands Enterprise: Revealing an Innovative Corporate Structure Dedicated to Redefining Healthcare Value
9. Lexicon Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2011 Financial Results
11. Cumberland Pharmaceuticals Reports 2011 Annual Financial Results